Core Viewpoint - The article discusses the significant challenges faced by Eli Lilly, particularly in the context of its Alzheimer's drug and GLP-1 medications, highlighting the volatility in its stock price and the shifting dynamics in the pharmaceutical market [1][4][25]. Group 1: Recent Developments - Eli Lilly's Alzheimer's drug, Donanemab, showed a cognitive decline relief rate of 35%-40%, but concerning side effects were noted, with 1 in 4 patients experiencing brain edema [3]. - The oral GLP-1 drug, Orforglipron, demonstrated a 14.7% weight loss, but its performance was overshadowed by the injection alternatives [3]. - In Q3 2024, Zepbound's sales were $1.26 billion, significantly below market expectations, while Mounjaro's sales of $3.11 billion also missed targets [4][6]. Group 2: Market Dynamics - The GLP-1 market is experiencing a 45% industry growth rate, but Eli Lilly's sales growth has stalled, raising concerns among investors about real demand versus inventory adjustments [4][6]. - The competition in the diabetes and weight loss drug markets is intensifying, with rivals like Novartis and Pfizer increasing their presence [9]. - The potential for price reductions due to Medicare negotiations poses a risk to profit margins, with historical data indicating significant price drops in similar scenarios [14][22]. Group 3: Future Outlook - Eli Lilly faces a critical juncture; if Q1 2025 data does not show improvement, market confidence may wane [7]. - The company must navigate three key challenges: proving that demand ceilings have not been reached, maintaining technological advantages, and justifying valuation premiums [10]. - The anticipated market for GLP-1 drugs could reach $200 billion by 2030, but competitive pressures and pricing strategies will significantly impact this projection [12][23]. Group 4: Pricing and Market Penetration - Historical trends in insulin pricing suggest that each new competitor could lead to a 3%-5% decrease in price levels within the GLP-1 market [18]. - The article highlights that while the market for GLP-1 drugs is expected to grow, the actual sales may not align with penetration rates due to competitive pricing pressures [23]. - Eli Lilly's pricing strategy will need to balance between maintaining market share and managing profitability amid increasing competition [14][22].

青侨阳光医药投资 - 行业思考 1 标准化程度和医生依赖度的差异， 是"药VS械VS院"业务不同特性的重要来源 "医药"里的"医"主要指医疗器械和医疗机构，"药"主要指中药、化药、生物药等药品。从这点来说，"药品、 器械、医院等医疗机构"是医药行业最核心3大业务类别。除此之外的医药细分，多数可以看成是这3类业务的 配套产业，比如原料药、CRO、CMO等可以看成是药品的配套，分销商、药店等可以看成是药品和器械的配 套，三方诊断、医疗信息化等可以看成是医疗机构的配套。 从欧美日等发达国家过去几十年的历史经验看，在医药行业相对成熟的主流经济体中，"药"的资本回报率最为 可观，"械"的资本回报率也相当优秀，但"院"的资本回报率比较糟糕。 比如有很多人统计过美股不同行业的历史ROIC，其中： 这与我们的直觉感受是一致的，虽然药品和器械占整个医药行业总盘子不到20%，但我们闭着眼睛也能数出几 十个声名显赫、历史回报强劲的来自美国、欧洲、日本的制药企业和医疗器械企业；但对于占行业总盘子超 60%的医疗服务业务，著名的海外上市医院集团我们可能一只手的指头都数不完。 为什么会这样？一个重要原因是这 三类业务在标准化程度和医生依 ...